TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01656057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin + acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin + acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam + acetaminophen dissolved in 50 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam + acetaminophen dissolved in 50 ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-8
Description: iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-8
Description: iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-8
Description: iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: iv. saline infusion 40 ml/hour for the first 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: iv. saline infusion 40 ml/hour for the first 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: iv. saline infusion 40 ml/hour for the first 60 minutes
Study: NCT00355784

Intervention type: OTHER
Group type: OTHER
Intervention: overfeeding
Description: overfeeding 2000kcals/day above energy requirements for 14d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overfeeding
Description: overfeeding 2000kcals/day above energy requirements for 14d
Study: NCT01933542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets identical to the chlorzoxazone tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorzoxazone
Description: Two 250 mg chlorzoxazone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
Study: NCT01126528

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 35,000 IU per week, started at 26-29 weeks gestation, until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
Study: NCT04522635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (100 ml of Albumin 25%)
Description: single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
Study: NCT00355784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overfeeding
Description: overfeeding 2000kcals/day above energy requirements for 14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone treatment
Description: growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone treatment
Description: growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
Study: NCT01237977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A(Meditoxin®)
Description: single administration, Day 0, 20U

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A(Botox®)
Description: single administration, Day 0, 20U
Study: NCT04072809

Intervention type: OTHER
Intervention: No intervention
Description: This study does not involve any interventions.
Study: NCT03264222

Intervention type: OTHER
Group type: OTHER
Intervention: Security screening procedure
Description: Screening procedure with security device (model QPS 100)
Study: NCT04522635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: (100 ml of Albumin 25%)
Description: single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
Study: NCT01452685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Leuprorelin acetate
Description: TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
Study: NCT03844620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Procedure
Description: Undergo ctDNA testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given by mouth
Study: NCT02440191

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3DCRT
Description: conventional radiotherapy
Study: NCT04881786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic forces
Description: 56g force and 224g force

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic forces
Description: 56g force and 224g force
Study: NCT02552901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ICG Dose
Description: least efficacious dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ICG dose
Description: per package insert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg/kg ICG dose
Description: per package insert
Study: NCT00564512

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Campath
Description: Fludarabine-Cyclophosphamide-Campath (FCCam)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Fludarabine-Cyclophosphamide-Rituximab (FCR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
Study: NCT03007602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Extremity Aerobic Exercise
Description: Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department.
Study: NCT01574885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halotherapy
Description: The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
Study: NCT00003126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
Study: NCT02631486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Passive exercises, active exercises, strengthening, stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Passive exercises, active exercises, strengthening, stretching
Study: NCT03021330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunomycin and Cytarabine (DA Regimen)
Description: Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)
Description: Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3.
Study: NCT02440191

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT
Description: conventional radiotherapy
Study: NCT06401902

Intervention type: PROCEDURE
Intervention: carotid clamping
Description: Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.

Intervention type: PROCEDURE
Intervention: carotid clamping
Description: Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
Study: NCT02427412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
Study: NCT02109172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Study: NCT03305848

Intervention type: DRUG
Group type: OTHER
Intervention: Nitrostat 0.4Mg Sublingual Tablet
Description: Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.
Study: NCT01379846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-816+ DPT-TAKEDA
Description: TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB+ DPT-TAKEDA
Description: ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
Study: NCT04648787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-integrated care
Description: One week after admission, the parents of premature infants were informed by telephone one day in advance to enter the ward for family participation nursing, and the guidance of daily life nursing for premature infants was given on the same day, including hand hygiene, breast feeding, pacification, changing diapers, bathing and establishment of parent-child relationship. Before discharge, theparents of premature infants should be informed by telephone one day in advance to enter the ward again for family participation nursing, and half a day's guidance was given, including observation and treatment of common symptoms and signs, guidance of home safety prevention and learning to write diary of premature infants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: traditional nursing
Description: In hospital education: the health education manual for premature infants will be issued at the time of discharge; the patient's condition will be answered by telephone from 14:00 to 16:00 every day.
Study: NCT04020523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI sequence
Description: The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
Study: NCT01026246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used will be normal saline (0.9 percent NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used will be normal saline (0.9 percent NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used will be normal saline (0.9 percent NaCl).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
Study: NCT01574885

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
Study: NCT01534195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
Description: One drop in each eye, four times/day for 8 days.
Study: NCT01026246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
Study: NCT03282955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipidem
Description: Lipoplus i.v. lipid emulsion for parenteral nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT 20%
Description: Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition
Study: NCT02109172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02513862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma Harvest Technique
Description: 15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
Study: NCT04400162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usability of the CCT
Description: Evaluation of the usability of the provided training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usability of the CCT
Description: Evaluation of the usability of the provided training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Changes in regards to the depressive disorder
Description: Evaluation of depressive symptoms and whether they change in regards to the provided training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changes in regards to the depressive disorder
Description: Evaluation of depressive symptoms and whether they change in regards to the provided training.
Study: NCT04669119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bromelain/Boswellia Serrata Casperome
Description: Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bromelain/Boswellia Serrata Casperome
Description: Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
Study: NCT01534195

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tears Naturale II Ophthalmic Solution
Description: one drop in each eye, four times/ day (QID) for 8 days
Study: NCT02669121

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NoV Placebo-matching Saline
Description: NoV placebo-matching saline (0.9% sodium chloride).
Study: NCT04669119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centella Asiatica/Vitamins
Description: Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
Study: NCT02669121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV GI.1/GII.4 Bivalent VLP Vaccine
Description: NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
Study: NCT00549575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L ARG
Description: Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After double blind randomization, patients received a placebo.
Study: NCT03516656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard heparin dose
Description: Patients will be placed on heparin infusions per their surgeon's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Real time heparin dose adjustment
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
Study: NCT02463773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Diaphragmatic excursion ultrasound assessment
Study: NCT02558777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent nurse-led intervention
Description: Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs.
Study: NCT03302637

Intervention type: OTHER
Intervention: 16S rRNA gene sequencing assay
Description: extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.

Intervention type: OTHER
Intervention: 16S rRNA gene sequencing assay
Description: extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
Study: NCT03191045

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI and concomitant perfused manometry of bowel motility
Description: We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.